Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements. BBCR Consulting offers world-class regulatory, clinical research, and biomarker consulting services that provide high-value, and support our clients’ operational and functional needs. Our process is designed […]
Medical Affairs and Clinical Research
Boston Biotech Clinical Research specializes in rare disease, working with biotech, pharmaceutical, investors and device companies to help streamline the clinical trial process.
May 11th, 2022 | Medical Affairs and Clinical ResearchBBCR’s team of experts help clients match treatments to rare genetic conditions and unsolved diseases, then work cohesively with a product developer on the best plan to market.
May 4th, 2022 | Medical Affairs and Clinical ResearchDid you know that about a third of orphan approvals by the FDA since the program began have been mostly for repurposed mass-market drugs? Drug repurposing acts to lower the need for early stage clinical trials and can help identify new uses for existing drugs. We invite you to learn more about how BBCR can […]
BBCR’s team of experts help to streamline clinical development strategies for biotech companies, venture capitalists, investors, research organizations and pharmaceutical companies.
April 26th, 2022 | Medical Affairs and Clinical ResearchOur experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements. BBCR’s medical experts optimize development strategies for biotech companies, venture capitalists, investors, research organizations and pharmaceutical companies. At BBCR Consulting, our team specializes in rare disease […]
Insight into Pediatric Rare diseases and Rare Pediatric Disease Designation – Boston Biotech Clinical Research
April 14th, 2022 | Medical Affairs and Clinical ResearchPediatric Rare diseases and Rare Pediatric Disease Designation FDA will award priority review vouchers to sponsors of certain rare pediatric disease product applications that meet the criteria specified. Section 529 of the FD&C Act is intended to encourage development of new drug and biological products for the prevention and treatment of rare pediatric diseases. Section […]
BBCR has extensive experience in biologics for rare diseases and can assist with the development of a targeted strategy to meet your study needs.
April 12th, 2022 | Medical Affairs and Clinical ResearchBiologic treatments show promise in providing clinical solutions to a variety of diseases including rare cancers and precision medicine. Related Services Include: Indications analysis and prioritization Strategic drug assessment Clinical study design and protocol Biomarker strategy Early Clinical Development FDA meeting and submission Pre-ND integrated development plan CRO and project management Study remediation and rescue
BBCR embraces innovative strategy consulting for effective clinical development plan and regulatory strategy. Learn more about BBCR and how we help clients succeed.
April 5th, 2022 | Medical Affairs and Clinical ResearchOur industry needs innovative strategies, and reduced-risk clinical trials. BBCR clinical development services and drug development consulting integrates real world evidence into clinical development plans and regulatory strategies. Focus must go to cost containment and value-based developments that allow sponsors to move more treatments to market faster. BBCR’s team expertise in rare diseases and precision […]
The Strategic Clinical Innovation Organization method, developed by BBCR, can help streamline the clinical trial process by operating on the fundamental principle that strategy and design are keys for the success of drug and medical device development.
March 29th, 2022 | Medical Affairs and Clinical ResearchBiologics can provide opportunity for identifying a treatment or cure in cases of rare disease. BBCR team experience in biologics for rare diseases included rare cancers and precision medicine can help develop a targeted strategy including studies with fewer patients that control for safety issues.
March 23rd, 2022 | Medical Affairs and Clinical ResearchBBCR team experience in biologics for rare diseases included rare cancers and precision medicine can help develop a targeted strategy including studies with fewer patients that control for safety issues. Indications analysis and prioritization Strategic drug assessment Clinical study design and protocol Biomarker strategy Early Clinical Development FDA meeting and submission Pre-ND integrated development plan […]
BBCR partners with small and medium sized drug and device biotechnology firms. Our clients are clinical researchers and innovators looking for an efficient path to approval, and come to us from across the globe. Reach out today to learn more.
March 16th, 2022 | Medical Affairs and Clinical ResearchThe BBCR mission is to simplify clinical research, encourage cost-effective trials, and help innovators navigate through the regulatory process. Who We Serve: Small & Medium Sized Biotech Companies currently moving from pre-clinical studies toward clinical trials in need of interim Chief Medical Officer in need of regulartory strategy consultancy in need of preparing a pre-IND meeting […]